Key Drivers
- Gross Margin
- Cash Pressure
- Rich Multiple
AIAI Summary
PHAR has shifted from a cheap-biotech setup to a prove-it transition story: investors will likely stay skeptical until Joenja's Japan/EU/pediatric catalysts clearly offset RUCONEST decline and translate into stronger, sustained cash flow, especially with the stock still below key resistance and profitability remaining thin.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Cash Pressure
- •Rich Multiple
PHAR has strong gross margins and solid liquidity, but thin earnings, weaker cash generation, and a rich valuation make the stock difficult to justify on current results.
Price Behavior
Key Price Behavior Insights:
- •Broken trend
- •Oversold bounce
- •Overhead resistance
PHAR is still in a clear downtrend over the last month after the sharp May 7 breakdown, with $12.0–$12.6 acting as near-term support, $16.4 as major resistance, and only an oversold bounce setup unless buyers reclaim resistance.
Sharp drop from around $16 to about $12 on
Sentiment & News
Key News Insights:
- •RUCONEST decline
- •Joenja growth
- •2026 catalysts
Pharming's Q1 update showed RUCONEST revenue pressure from inventory drawdown and market exits, but strong Joenja growth and upcoming pediatric/regional milestones keep the outlook constructive.
The news is modestly positive for PHAR as legacy softness is increasingly offset by Joenja momentum and near-term regulatory and clinical upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings